OLEMA PHARMACEUTICALS, INC. (OLMA) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 190.19M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 31.57M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -221.13M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $190.19M | (m) | $31.57M | $-221.13M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $176.31M | (m) | $23.36M | $-201.81M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $157.70M | (m) | $17.59M | $-178.70M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $146.78M | (m) | $19.64M | $-165.38M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $140.05M | (m) | $21.02M | $-157.13M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $125.26M | (m) | $22.05M | $-142.79M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $124.52M | (m) | $22.58M | $-142.26M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $118.09M | (m) | $20.61M | $-135.91M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $104.32M | (m) | $19.09M | $-121.63M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $93.20M | (m) | $17.54M | $-109.70M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $86.14M | (m) | $17.26M | $-104.96M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $81.85M | (m) | $17.77M | $-101.76M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $80.03M | (m) | $17.94M | $-101.64M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $89.09M | (m) | $18.49M | $-113.34M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $82.27M | (m) | $18.83M | $-106.99M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $76.67M | (m) | $18.59M | $-101.53M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $71.56M | (m) | $18.48M | $-96.07M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $56.42M | (m) | $17.67M | $-79.30M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $51.10M | (m) | $15.91M | $-71.49M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $13.70M | (m) | $3.11M | $-21.53M | $653.00K | (m) | (m) | -32.97× | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $3.92M | (m) | (m) | $-4.32M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |